myPOS Opens First Flagship Store in Paris
Europe's fastest growing payment solutions provider, opens a store in Paris. This is the 7th European store for the company, aiming to strengthen its physical presence and getting closer to its customers in France.
Since its launch in 2014, myPOS has been helping SMEs grow through payments technology. Not only it provides a range of multifunctional POS terminals at super-affordable prices (from € 29 to only € 349), but also enables every merchant with a free multi-currency account into which all card payments are settled immediately, at no extra cost.
“myPOS is the first and only payment solution to provide instant pay-out to the merchant account. Before myPOS, business owners had to wait for days and weeks to access their money.’’ – says Christo Georgiev, founder of myPOS – ‘’We hope that French businesses will take advantage and improve their business operations with myPOS, resulting in positive cashflows’’.
The myPOS devices read chip & pin, magnetic stripe and contactless cards, and accept popular card operators such as VISA, Mastercard, American Express, JCB, Union Pay, plus European payment schemes such as Bancontact and iDEAL. Mobile wallets are welcomed too - Apple Pay, Google Pay and Samsung Pay.
myPOS is quickly gaining a foothold in Europe covering 30+ countries, having gained the trust of more than 80,000 clients.
One of the factors to this success is also the opening of series of flagship stores across Europe, something no other European payments provider has done yet, starting with London, Amsterdam, Sofia, Milan and Barcelona in 2018, and adding Antwerp and Paris in 2019, with more to come.
In February 2019, the Berlin Merchants Payments Ecosystem jury awarded myPOS the Best POS Innovation Award. Later this year, myPOS was also nominated by the European Business Awards for the Award for Innovation and by the 2019 Payment Awards for Best Merchant Acquirer/Processor.
About myPOS World Ltd
myPOS World Ltd is a fintech company operating the myPOS platform across Europe. The myPOS e-money accounts and payment services are provided by a myPOS-owned UK E- Money Institution, authorised and regulated by the FCA and by an associated EU-licensed E- Money Institution, a direct member of MasterCard, VISA, Amex, JCB, UnionPay and other card schemes.
myPOS headquarters is at Level 24, The Shard, London Bridge Street, London SE1 9SG, UK.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190924005043/en/
Contact information
Irina Stefanova, PR manager
Email: pr@mypos.com
Telephone: +44 20 3129 3086
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Knopp Biosciences Presents Data Further Characterizing Its Lead Kv7.2 Activator Drug Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting9.12.2019 20:00:00 EET | Press release
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today presented data characterizing KB-3061, the lead molecule in the Company’s Kv7 ion channel platform, at the American Epilepsy Society’s (AES) 2019 Annual Meeting in Baltimore, Maryland. Knopp is advancing the development of KB-3061 as a potential precision medicine treatment for the rare, neonatal disease KCNQ2 epileptic encephalopathy (KCNQ2-EE), a genetically defined disease associated with seizures beginning in the first days of life and profound neurodevelopmental delay. The disease is caused by dominant-negative mutations in the KCNQ2 gene, which produces a potassium channel, Kv7.2, critical to early brain development. Data presented at AES by Knopp scientists and its academic collaborators support the continued development of KB-3061 as a potential treatment for children with KCNQ2-EE. K
Murray Energy Corporation Posts Information to its Website Related to Murray Metallurgical9.12.2019 18:46:00 EET | Press release
Beginning on December 2, 2019, Murray Energy Corporation (the “Company”) engaged in confidential discussions under separate confidentiality agreements with certain members of an ad hoc group of superpriority lenders related Murray Metallurgical Coal Holdings, LLC and its subsidiaries (collectively, “Murray Metallurgical”). The confidentiality agreements require the Company to publicly disclose all material non-public information provided to such lenders on or prior to 8:30am (New York time) on December 9, 2019. The Company has posted certain previously undisclosed material to its website to satisfy its disclosure obligations under the confidentiality agreements. Such information can be viewed at the Investors portion of the Company’s website, located at murrayenergycorp.com/investors. Further inquiries should be directed to media@coalsource.com. Safe Harbor Statement The materials referenced in this release and posted to our website include forward-looking statements. A variety of fact
Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 20199.12.2019 18:00:00 EET | Press release
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting that underscore its commitment to advancing treatments for rare bleeding disorders by incorporating real-world data and developing innovative adeno-associated virus (AAV) gene therapies. Understanding Real-World Evidence to Advance Patient-Centric Innovation in Bleeding Disorders Real-world evidence from studies across many of Takeda’s portfolio of treatments for hemophilia demonstrate the cost savings and patient benefits resulting from ongoing personalized treatment. However, in von Willebrand disease, real-world evidence highlights the ongoing unmet clinical need for personalization, as it may enable improved treatment outcomes. Insights presented at ASH include: ADYNOVATE ® [Antihemophilic Factor (Recombinant), PEGylated]: In the poster “Real-World Age-Stratified FVIII Consumption and Bleed Outcom
Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting9.12.2019 18:00:00 EET | Press release
Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced additional analyses of results from the ECHELON-1 and ECHELON-2 frontline phase 3 trials of ADCETRIS® (brentuximab vedotin). These analyses were presented at the 61st Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2019 in Orlando, Fla. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma and expressed on the surface of several types of peripheral T-cell lymphomas (PTCL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005169/en/ The ECHELON-1 analysis highlighted a four-year update of the phase 3 clinical trial in a poster presentation. ECHELON-1 is evaluating ADCETRIS in combination with AVD (Adriamycin [doxorubicin], vinblastine and dacarbazine) compared to ABVD (Adriamycin [doxorubicin], bleomycin, vinblasti
Altasciences to Conduct Clinical Trial for Opioid Use Disorder Under NIH Funding9.12.2019 17:39:00 EET | Press release
Altasciences has been selected by Indivior PLC to conduct "A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers", pursuant to the National Institutes of Health (NIH) Funding Opportunity Announcement RFA-DA-19-002, dedicated to the development of medications to prevent and treat opioid use disorder and overdose. The grant was made to Indivior by the NIH in fiscal year 2019, to apply scientific solutions to reverse the national opioid crisis. In March 2018, Indivior entered into a license agreement with C4X Discovery Holdings PLC (C4X) whereby Indivior obtained exclusive global rights to develop and commercialize INDV-2000 (C4X_3256). The first-in-human, single-ascending-dose study will be conducted in two parts — Part I: double-blind, placebo-controlled, randomized, single-ascending-dose study in fasted condition. Part II:
Elliott Statement on Alexion9.12.2019 17:22:00 EET | Press release
Funds advised by Elliott Advisors (UK) Limited (together “Elliott” or “we”) acknowledge the statement issued by Alexion Pharmaceuticals, Inc. (“Alexion” or “the Company”) on Friday. Elliott confirms that it has had a multiyear, constructive and private engagement with Alexion that has led to value-creative changes at the Company. Despite two years of strong execution that bolstered the Company’s strategic value, we believe Alexion remains significantly undervalued by the market. Elliott is encouraged by the Board’s public commitment to evaluate any inbound interest and its overall commitment to shareholder value creation. Elliott remains of the view that Alexion would be a highly valuable strategic and financial asset for a number of larger pharmaceutical companies. We also continue to believe that a proactive approach would maximise the chance of an optimal outcome. We look forward to continuing our dialogue with the Company in an effort to close the gap between its current share pric
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom